ArticleCureus2025
Risk Evaluation of Point-of-Care Testing (POCT) Devices: Insights From a Tertiary Care Hospital.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Cryoprotective strategies for frozen erythrocytes in POCT whole blood reference materials progress and challenges.Analytical and bioanalytical chemistry · 2026Review
- APPLICATION LEVELS OF PRINCIPLES OF POCT IMPLEMENTATION, MANAGEMENT, AND MAINTENANCE THROUGH THE PERCEPTIONS OF HEALTHCARE PROFESSIONALS AT A TERTIARY HOSPITAL IN UYO, AKWA STATE, NIGERIA.Annals of Ibadan postgraduate medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction Point-of-care testing (POCT) entails conducting a test near a patient, delivering rapid results outside the traditional laboratory setting. Even though point-of-care testing offers the advantage of rapid test results and enables quicker medical decisions, it also introduces unique risks of errors, raising concerns regarding the quality and reliability of these results. This study focuses on a comprehensive risk assessment of POCT devices in a tertiary care setting to evaluate performance, identify potential errors, categorize risks, and implement strategies to enhance their safety and effectiveness. Method The study was conducted as a prospective, observational, nonrandomized study in a tertiary care hospital. A total of 53 devices were selected purposively which were used across various departments of the hospital, including emergency, intensive care unit (ICU), critical care unit (CCU), operation theatre (OT), maternity, and obstetrics. The assessment covered a range of POCT devices: blood gas analyzers, cardiac biomarkers, coagulation analyzers, and glucometers. In POCT devices, risk assessment identifies potential hazards that may arise throughout the entire testing process, encompassing the pre-analytical, analytical, and post-analytical phases. Performance of the devices was evaluated using comparison with standard guidelines and errors were identified using direct observations and incident reports. The Failure Modes and Effect Analysis (FMEA) template served as a tool for on-site risk assessment, facilitating the systematic identification and evaluation of potential failure modes and their corresponding effects. A comparison of the scored risk priority number (RPN) before and after interventions was conducted to assess the effectiveness of the implemented suggestions or action plans for mitigating the identified risks. Results Inaccurate patient identification, clotted samples due to improper mixing, patient injury, and delays in sample transportation were the key risks identified during the pre-analytical phase. Delays in sample processing, improper handling of internal quality control materials, improper handling of external quality assessment scheme samples, failure to adhere to original equipment manufacturer instrument maintenance protocols, mishandling of patient samples, and inadequate quality checks were a few observations during the analytical phase. Reporting errors, delayed turnaround times (TAT), and delays in reporting panic values were observed during the post-analytical phase. Implementing quality control measures, real-time monitoring, automation, comprehensive staff training, and risk mitigation strategies served to enhance the reliability and efficiency of POCT devices. Conclusion In point-of-care testing devices, risk assessment identifies potential hazards that may arise throughout the entire testing process, encompassing the pre-analytical, analytical, and post-analytical phases. Continuous monitoring and improvement efforts are essential for adapting to evolving risks in POCT devices.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.